Multimorbidity guidelines: past, present and future_Chinese Journal of Evidence-Based Medicine

Authors：

WANG Zijun ^1,2,3,4 , SHI Qianling ^2,3,4,5 , GONG Enying ^6,7 , LUO Xufei ^1,2,3 , XUN Yangqin ⁷ , SHAO Ruitai ^6,7 ,  CHEN Yaolong ^1,2,3,4,8

1. Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, P. R. China;
2. Research Unit of Evidence-based Evaluation and Guidelines, Chinese Academy of Medical Sciences, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, P. R. China;
3. Key Laboratory of Evidence Based Medicine of Gansu Province, Lanzhou 730000, P. R. China;
4. Institute of Health Data Science, Lanzhou University, Lanzhou 730000, P. R. China;
5. The First Clinical Medical College, Lanzhou University, Lanzhou 730000, P. R. China;
6. State Key Laboratory of Respiratory Heatth and Multimorbidity, Chinese Academy of Medical Science, Beijing 100005, P. R. China;
7. School of Population Medicine and Public Health, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100005, P. R. China;
8. WHO Collaborating Centre for Guideline Implementation and Knowledge Translation, Lanzhou University, Lanzhou 730000, P. R. China;

Corresponding author：

CHEN Yaolong, Email: chevidence@lzu.edu.cn

Keywords：

Multimorbidity; Clinical practice guideline; Guideline development

DOI：

10.7507/1672-2531.202401171

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Multimorbidity is becoming a major issue in global health due to the increased prevalence of chronic diseases and the accelerated aging of the population. Clinical practice guidelines, as key tools for guiding clinical practice, play an important role in the field of multimorbidity, but also face many challenges. In this paper, we will review the necessity of developing multimorbidity guidelines, the current situation, challenges and opportunities, and on this basis, we will put forward our thoughts and suggestions to promote the development of guidelines in the field of multimorbidity in China.

Citation： WANG Zijun, SHI Qianling, GONG Enying, LUO Xufei, XUN Yangqin, SHAO Ruitai, CHEN Yaolong. Multimorbidity guidelines: past, present and future. Chinese Journal of Evidence-Based Medicine, 2024, 24(6): 621-625. doi: 10.7507/1672-2531.202401171 Copy

1.	Van Lerberghe W. The world health report 2008: primary health care: now more than ever. World Health Organization, 2008.
2.
3.
4.
5.
6.
7.	Institute of Medicine. Clinical practice guidelines we can trust. Washington DC: National Academies Press, 2011.
8.	National Institute for Health and Care Excellence. Multimorbidity: clinical assessment and management (NICE clinical guideline 56). 2016.
9.
10.
11.	National Institute for Health and Care Research. Multiple long-term conditions (multimorbidity): making sense of the evidence. 2021.
12.
13.	National Institute for Health and Care Excellence. Older people with social care needs and multiple longterm conditions. 2015.
14.	NICE Medicines and Prescribing Centre (UK). Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes. Manchester: National Institute for Health and Care Excellence (NICE), 2015.
15.
16.
17.
18.
19.
20.
21.
22.
23.	中华人民共和国中央人民政府国务院. 《“健康中国2030”规划纲要》. 2016.
24.
25.
26.
27.	Xu X, Mishra GD, Jones M. Evidence on multimorbidity from definition to intervention: an overview of systematic reviews. Ageing Res Rev, 2017, 37: 53-68.
28.	中国医学科学院北京协和医学院. 中国人全生命期共病队列研究(人生队列研究)启动. 2023.
29.
30.
31.

1. Van Lerberghe W. The world health report 2008: primary health care: now more than ever. World Health Organization, 2008.
2.
3.
4.
5.
6.
7. Institute of Medicine. Clinical practice guidelines we can trust. Washington DC: National Academies Press, 2011.
8. National Institute for Health and Care Excellence. Multimorbidity: clinical assessment and management (NICE clinical guideline 56). 2016.
9.
10.
11. National Institute for Health and Care Research. Multiple long-term conditions (multimorbidity): making sense of the evidence. 2021.
12.
13. National Institute for Health and Care Excellence. Older people with social care needs and multiple longterm conditions. 2015.
14. NICE Medicines and Prescribing Centre (UK). Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes. Manchester: National Institute for Health and Care Excellence (NICE), 2015.
15.
16.
17.
18.
19.
20.
21.
22.
23. 中华人民共和国中央人民政府国务院. 《“健康中国2030”规划纲要》. 2016.
24.
25.
26.
27. Xu X, Mishra GD, Jones M. Evidence on multimorbidity from definition to intervention: an overview of systematic reviews. Ageing Res Rev, 2017, 37: 53-68.
28. 中国医学科学院北京协和医学院. 中国人全生命期共病队列研究(人生队列研究)启动. 2023.
29.
30.
31.

Next Article
Guideline for the rehabilitation treatment of osteoporosis (2024 edition)

Chinese Journal of Evidence-Based Medicine

Multimorbidity guidelines: past, present and future

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content